Indefinite Azacitidine Treatment Until Progression May Provide Long-Term Disease Control in Elderly Patients with Acute Myelogenous Leukemia
The prognosis of acute myelogenous leukemia (AML) is poor in elderly patients. The mean survival rates at second and fifth years for AML were 10% and 2%, respectively. Here our aim was to demonstrate that the survival rate can be prolonged by long-term azacitidine (AZA) treatment. Complete remission...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Publishing House
2018-07-01
|
| Series: | Bezmiâlem Science |
| Subjects: | |
| Online Access: |
http://bezmialemscience.org/archives/archive-detail/article-preview/ndefinite-azacitidine-treatment-until-progression-/20151
|